Multidrug Infusion for Pain Control via Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain management methods for aged patients and those with end-stage malignancies often fail to provide effective and durable pain relief without unacceptable side effects, due to age-related co-morbidities and limitations in systemic opioid use.
Innovation Solution
A formulation comprising an opioid, a Na channel blocker, an alpha2-receptor agonist, and an opioid mu or delta receptor competitive antagonist, combined with an intravenous anesthetic/neurologic agent, administered via epidural, paravertebral, peripheral nerve, intra-articular, synovial bursa, sub-cutaneous, or intravenous routes, or in combination, to provide efficient pain management and cognitive function improvement.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic opioids are used for pain management in aged patients and those with end-stage malignancies, then pain relief is achieved, but side effects become unacceptable
Solution Approach 1:
The patent divides the single systemic opioid treatment into multiple separate drug components administered via different routes (epidural, paravertebral, peripheral nerve, intra-articular, synovial bursa, sub-cutaneous, or intravenous). Each drug targets specific pain mechanisms locally, segmenting the therapeutic action to achieve effective pain relief while minimizing systemic side effects in aged patients and those with end-stage malignancies.
2Reliability
If multiple drugs are combined for pain management, then pain control effectiveness improves, but treatment complexity increases
Solution Approach 1:
The patent combines multiple drugs with different mechanisms of action (opioid, Na channel blocker, alpha2-receptor agonist, opioid antagonist, and intravenous anesthetic/neurologic agent) into a single multidrug infusion formulation. This merging approach maintains effective pain control while simplifying administration through a unified delivery system, reducing the burden of managing multiple separate treatments.
Solution Approach 2:
The multidrug infusion formulation serves multiple functions simultaneously: analgesia, cognitive function improvement, and side effect reduction. The formulation can be administered through various routes (epidural, paravertebral, peripheral nerve, intra-articular, synovial bursa, sub-cutaneous, or intravenous) to address different pain types and locations, making it a universal solution for complex pain management cases.
3Reliability
If opioid dose is increased to improve pain relief, then pain control improves, but systemic side effects increase
Solution Approach 1:
The patent applies local quality by administering drugs directly to the site of pain or near the pain pathway through localized routes (epidural, paravertebral, peripheral nerve, intra-articular, synovial bursa). This ensures high concentration of analgesics at the target site for effective pain control while maintaining low systemic concentrations, thereby minimizing systemic side effects in vulnerable patients.
Data Source
Figure 1
AI summary
The present invention relates to a formulation comprising an opioid, a Na channel blocker, an alpha2-receptor agonist, an opioid mu or delta receptor competitive antagonist and an intravenous anesthetic and/or a neurologic acting agent for use in pain control and/or cognitive function improvement.